Skip to main content
An official website of the United States government

lenvatinib mesylate

View Patient Information
A synthetic, orally available inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2, also known as KDR/FLK-1) tyrosine kinase with potential antineoplastic activity. Lenvatinib mesylate blocks VEGFR2 activation by VEGF, resulting in inhibition of the VEGF receptor signal transduction pathway, decreased vascular endothelial cell migration and proliferation, and vascular endothelial cell apoptosis.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:E7080 mesylate
multi-kinase inhibitor E7080 mesylate
US brand name:Lenvima
Chemical structure:4-[3-chloro-4-(N'-cyclopropylureido)phenoxy]7-methoxyquinoline-6-carboxamide mesylate
6-quinolinecarboxamide, 4-[3-chloro-4-[[(cyclopropylamino)carbonyl]amino]phenoxy]- 7-methoxy-, methanesulfonate (1:1)
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search